Study (ref.) | Median follow-up, months | bPFS, % | Toxicity scoring system | Acute toxicity, % | Late toxicity, % | ||
---|---|---|---|---|---|---|---|
GU | GI | GU | GI | ||||
Tandberg [30] | 38.6 | 78.4a (4 years) | CTCAE v4.0b/RTOGc | ≥ G2: 22; G3: 1d | G2: 5; ≥ G3: 0 | G2: 39; ≥ G3: 11 | G2:10; G3: 1d |
Kruser [33] | 32.4 | 67 (4 years) | RTOG | G2: 6.4; G3: 1d | G2: 14; ≥ G3: 0 | G2: 15; ≥ G3: 0 | G2: 4; ≥ G3: 0 |
Lewis [31] | 48 | 75 (4 years) | CTCAE v4.0b/RTOGc | G2: 4; ≥ G3: 0 | G2: 4; ≥ G3: 0 | G2: 39; G3: 28 | ≥ G3: 2d |
Cuccia [32] | 30 | 73 (3 years) | CTCAE v4.0 | G2: 4; ≥ G3: 0 | G2: 18; ≥ G3: 0 | G2: 2.6; G3: 2.6 | G2: 6.6; ≥ G3: 0 |
Barra [34] | 15.5 | Not reported | CTCAE v4.0b/RTOGc | ≥ G2: 0 | ≥ G2: 0 | G2: 3.3; G3: 3.3 | ≥ G2: 0 |
Alongi [35] | 22.8 | Not reported | RTOG | G2: 10; ≥ G3: 0 | G2: 20; ≥ G3: 0 | G2: 8; G3: 3 | ≥ G2: 0 |
Saldi [27] | 27 | Not reported | CTCAE v4.0 | G2: 8.9; ≥ G3: 0 | G2: 9.8; ≥ G3: 0 | Not reported | Not reported |
Katayama [26] | Not reported | Not reported | CTCAE v4.0 | ≥ G2: 0 | G2: 17.9; ≥ G3: 0 | Not reported | Not reported |
Gladwish [29] | 24 | Not reported | CTCAE v3.0b/RTOGc | G2: 3; G3: 3 | ≥ G2: 0 | ≥ G2: 1d | ≥ G2: 2d |
Macchia [28] | 30 | 86.5 (5 years) | RTOG | G2: 17.7; G4: 1d | G2: 24.2; ≥ G3: 0 | ≥ G2: 7.3 | ≥ G2: 1.1 |